Self-controlled Case Series Study for Acute Kidney Injury after Starting Proton Pump Inhibitors or Potassium-Competitive Acid Blocker in Patients with Cancer Using a Large Claims Database

Biological and Pharmaceutical Bulletin, Journal Year: 2024, Volume and Issue: 47(2), P. 518 - 526

Published: Feb. 22, 2024

To investigate the risk of acute kidney injury (AKI) in patients with cancer following initiation proton pump inhibitors (PPIs) and potassium-competitive acid blocker (PCAB), considering sex anti-cancer drug use. We conducted a self-controlled case-series study using Japan Medical Data Center claims data from 12422 who were prescribed PPIs or PCAB between January 2017 December 2019. Considering timing PPI PCAB, control period (days -120 to -1), 1 0 +30), 2 +31 +365) defined. assess incidence rate ratio (IRR) 95% confidence interval (CI) as ratio, we adjusted for drugs AKI. Additionally, also examined differences identify AKI was observed [2.05 (1.12-3.72), p = 0.0192], but slight reduction noted [0.60 (0.36-1.00), 0.0481]. A sex-specific increase only males during [2.18 (1.10-4.32), 0.0260], [0.48 (0.26-0.89), 0.0200]. identified an increased starting particularly within 30 d after initiation, emphasizing need vigilant monitoring management this patient population.

Language: Английский

---

Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(5), P. 595 - 610

Published: March 23, 2024

Acute kidney injury (AKI) frequently develops in patients receiving cancer therapy and requires a wide differential diagnosis due to possible role of unique drug-related factors, addition common pre- post-renal causes. Rapid development new molecular targeted anti-cancer drugs immunotherapies has opened unprecedented possibilities treatment at the price an increased spectrum renal side effects.

Language: Английский

---

Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology Group

International Journal of Gynecological Cancer, Journal Year: 2024, Volume and Issue: 34(9), P. 1359 - 1365

Published: July 1, 2024

To investigate the impact of cumulative cisplatin dose on clinical outcomes in locally advanced cervical cancer patients undergoing definitive chemoradiotherapy. A retrospective analysis was conducted 654 with stage IB3-IVA disease treated Radiotherapy applied as external beam pelvic or without para-aortic radiotherapy and brachytherapy. Concomitant chemotherapy form weekly 3 cisplatin. Data demographics, treatment protocols, dose, adverse effects, survival were collected. Statistical analyses, including univariate multivariate Cox regression models, used to assess factors influencing progression free overall survival. The median 210mg (range 40-320), ≥200mg 503 (76.9%) patients. Median follow-up 35 months 1-150). 5year rates 66.9% 77.1%, respectively. Multivariate identified poor performance status, non-squamous cell histology, presence lymph node metastases, hemoglobin <10g/dL before chemoradiotherapy prognostic for both whole group. When III cases evaluated separately, <200mg found be a significant factor (hazard ratio 1.79, 95%confidence interval 1.1 3.0, p=0.031). Our study showed that >200mg, particularly significantly improved Factors such anemia, toxicity related challenges, comorbidities critical considerations planning. These findings emphasize balance between maximizing therapeutic efficacy managing toxicity, guiding personalized approaches cancer.

Language: Английский

---

The Hepatoprotective Effects of Camellia sinensis on Cisplatin-Induced Acute Liver Injury

Life, Journal Year: 2024, Volume and Issue: 14(9), P. 1077 - 1077

Published: Aug. 28, 2024

Acute liver injury is an increasing global health problem. It a widespread side effect of cisplatin treatment in the clinic and can lead to failure if not treated promptly. Previous studies have revealed that green tea protect some organs from treatments. However, potential white prevent negative effects acute has been addressed so far. The purpose this study was investigate reduction cisplatin-induced rats receiving tea. Female Sprague Dawley with similar weight were selected study. Twenty-four divided into three groups eight animals each ad libitum nutrition provided. control given tap water only, while + group received at 0.5% weight/volume concentration for four weeks. At end fourth week, single dose (7 mg/kg) via intraperitoneal route. Five days after procedure, anesthetized. Liver tissues blood samples collected, which used biochemical histopathological analyses. According results, tissue MDA GSH, serum ALT, AST levels significantly increased compared group. Compared group, although MDA, AST, GSH lower only statistically different. examination immunohistochemical findings apoptotic cells, vascular congestion, sinusoidal dilatation This adverse event decreased In conclusion, exhibits ameliorating on injury.

Language: Английский

---

The SIRT6/BAP1/xCT signaling axis mediates ferroptosis in cisplatin-induced AKI

Cellular Signalling, Journal Year: 2024, Volume and Issue: 125, P. 111479 - 111479

Published: Oct. 23, 2024

Language: Английский

---

Age and Hypertension Synergize with Dehydration to Cause Renal Frailty in Rats and Predispose Them to Intrinsic Acute Kidney Injury

Laboratory Investigation, Journal Year: 2024, Volume and Issue: 105(3), P. 102211 - 102211

Published: Dec. 13, 2024

Language: Английский

---

Cancer-Associated Thrombotic Microangiopathy: Literature Review and Report of Five Cases

Life, Journal Year: 2024, Volume and Issue: 14(7), P. 865 - 865

Published: July 10, 2024

Thrombotic microangiopathy (TMA) is an anatomopathological lesion mediated by endothelial dysfunction and characterized the creation of microthrombi in small vessels. In patients with cancer, it may be due to toxicity secondary chemotherapy, tumor embolization, or hematopoietic progenitor transplantation. Cancer-associated TMA underestimated entity that generally appears final stages disease, although also initial manifestation underlying cancer. Support treatment necessary all cases and, depending on cause, different targeted therapies used. The prognosis very poor. this article we present a comprehensive review existing literature physiological mechanisms cancer-associated TMA. Afterwards, five clinical will presented who developed were diagnosed our Department 2023. We discussion causes triggered condition, possible reasons behind underestimation pathology, measures adopted.

Language: Английский

---

The Endocannabinoid System of the Nervous and Gastrointestinal Systems Changes after a Subnoxious Cisplatin Dose in Male Rats

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(10), P. 1256 - 1256

Published: Sept. 24, 2024

Background/Objectives: Cisplatin, a common chemotherapy agent, is well known to cause severe side effects in the gastrointestinal and nervous systems due its toxic pro-inflammatory effects. Although pharmacological manipulation of endocannabinoid system (ECS) can alleviate these effects, how affects ECS components remains poorly understood. Our aim was evaluate changes. Methods: Male Wistar rats received cisplatin (5 mg/kg, i.p.) or saline on day 0 (D0). Immediately after, serial X-rays were taken for 24 h Body weight recorded (D0, D1, D2 D7) behavioural tests performed D4. On D7, animals euthanized, tissue, dorsal root ganglia (DRGs) brain areas collected. Expression genes related assessed via Rt-PCR, while LC-MS/MS used analyse N-acylethanolamine levels tissue plasma. Results: Animals treated with showed reduction body weight. Cisplatin reduced gastric emptying during D0 decreased MAGL gene expression antrum at D7. Despite not causing mechanical heat sensitivity, we observed alterations prefrontal cortex (PFC) DRGs similar those seen other chronic pain conditions, including an increased CB1 L4/L5 PFC. Conclusions: A single dose i.p.), subnoxious, but capable inducing acute caused changes both systems. Modulating could potentially prevent chemotherapy-induced toxicity.

Language: Английский

---

Sex-dependent effects of CYP2E1 on the kidney and the protective potential of 4MP against cisplatin-induced nephrotoxicity

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 11, 2024

Abstract Cisplatin is an effective chemotherapeutic drug for the treatment of bladder cancer, though cisplatin-induced nephrotoxicity (CIN) occurs in approximately 20-30% patients, limiting its clinical use. Evidence has shown that cytochrome P450 2E1 (CYP2E1), a metabolism enzyme expressed proximal tubules, mediates production reactive oxygen species (ROS) during injury. Previously, we showed repurposed 4-methylpyrazole (4MP; fomepizole) blocks CYP2E1 activity and prevents acetaminophen-induced liver Here, investigated potential protective effects 4MP against CIN. Male female C57BL/6J mice were treated with single 20 mg/kg dose cisplatin 3 days (acute) or 9 mg/kg/week 4 weeks (repeated dosing regimen) without 50 as co-treatment. Our findings revealed acute induced severe histological tubular damage elevated plasma BUN creatinine levels male mice, but not mice. This difference correlated higher basal expression kidneys compared to We also found increased renal inhibition significantly reduced cell death primary normal human kidney cells. By contrast, cancer cells do express CYP2E1, did interfere cisplatin’s anti-cancer HTB9 study highlights critical role CIN suggests prophylactic therapeutic option prevent patients affecting anti-neoplastic effect. Impact Statement demonstrates (CYP2E1) mechanistic target prevention (CIN). It indicates plays important mediating sex-specific differences Finally, this reveals targeting 4methylpyrazole offers promising approach reducing settings while preserving efficacy cisplatin.

Language: Английский

---

Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives

Cancers, Journal Year: 2024, Volume and Issue: 16(23), P. 4078 - 4078

Published: Dec. 5, 2024

Cisplatin-based chemotherapy has long been the standard first-line (1L) treatment for metastatic urothelial carcinoma (mUC). However, up to 50% of patients with mUC may be ineligible cisplatin owing comorbidities, necessitating alternative primary options. Immune checkpoint inhibitors (ICIs) have emerged as a vital those unable receive cisplatin. Nevertheless, prognosis advanced UC remains dire and challenges persist in optimizing 1L therapy. Recent medical advancements redirected attention towards innovative drug combinations mUC. The combination enfortumab vedotin (EV) pembrolizumab shown significantly improved overall progression-free survival rates compared alone. This can used who are cisplatin-ineligible or require alternatives chemotherapy. While platinum-based continues essential many patients, approval EV treatments signifies major breakthrough cancer care. These therapies offer enhanced outcomes terms response highlight increasing relevance ICI-containing regimens frontline review provides an exhaustive overview current landscape explores new therapeutic strategies, aim facilitating clinical decision-making guiding strategies

Language: Английский

---